News

New Peer-Reviewed Publication Provides Further Insights into Mechanism of ISA Pharmaceuticals’ SLP® Immunotherapeutics

May 15, 2015

SLP®s modulate intratumoral macrophages required for tumor regression Leiden, The Netherlands, May 12, 2015 - ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally design...

Successful product lead identification underscores the strength of Merus’ platform in delivering human, full-length IgG bispecific antibodies

April 08, 2015

Utrecht, The Netherlands, 8th April 2015 - Merus B.V., a leader in developing best-in-class bispecific antibody therapeutics, announced today that it has reached a preclinical milestone in a bispecific antib...

ISA Pharmaceuticals Granted European Patent for the Intradermal Administration of ISA101

March 26, 2015

- Intradermal administration provides significant benefits compared to subcutaneous application - Leiden, The Netherlands, March 24, 2015 - ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company...

ISA Pharmaceuticals announces start of first Phase I/II clinical trial of its SLP®-AMPLIVANT® conjugates

March 02, 2015

• Leiden University Medical Center to study novel immunotherapeutic in HPV-positive head & neck cancer patients Leiden, The Netherlands, February 26, 2015 - ISA Pharmaceuticals B.V., a clinical-stage immu...

Merus starts Phase I/II clinical trial for MCLA-128, an ADCC-enhanced bispecific antibody for solid tumors

February 06, 2015

- First patient dosed in trial with potent bispecific antibody overcoming resistance to HER2-targeted therapies - Utrecht, The Netherlands, February 4, 2015 -- Merus B.V., a leader in developing best-in-c...

New Study Explains Synergy between Cancer Vaccine ISA101 and Chemotherapy

January 09, 2015

Tumor necrosis factor alpha (TNFα) produced by T cells following vaccination sensitizes tumor cells for eradication by certain chemotherapeutics Data published in Clinical Cancer Research support ongoing c...

After US court ruling, Merus reaffirms freedom to operate for its MeMo® transgenic mouse for therapeutic human antibodies

January 06, 2015

- Regeneron's '018 patent' is considered invalid and Merus not infringing - Utrecht, The Netherlands, January 5, 2015 - Merus B.V., a leader in developing best-in-class antibody therapeutics to treat canc...

Issuance of a new U.S. patent covering ORCA’s T1 oncolytic adenovirus technology

January 06, 2015

Nijmegen, The Netherlands - January 5th, 2015 - ORCA Therapeutics BV, a pioneer in the development of innovative oncolytic immunotherapies for treatment of cancer, announced today that it has secured key int...

Publication in Nature Supports ISA Pharmaceuticals´ Synthetic Long Peptide Immunotherapeutic Approach to Treat Cancer

November 27, 2014

- Synthetic Long Peptide (SLP®) immunotherapy achieves targeted tumor eradication comparable to checkpoint-blocking immunotherapy - New findings on antigens relevant for checkpoint blocking pave the way for...

Publication Demonstrates Strong Preclinical Efficacy of ORCA's lead Compound ORCA-010 in Different Tumor Models

September 25, 2014

Nijmegen, The Netherlands - September 25th, 2014 - ORCA Therapeutics BV, a pioneer in the development of innovative oncolytic virus immunotherapies for treatment of cancer, announced today the publication of...

Patent Position of Merus' MeMo Mouse Strengthened by Ruling of European Patent Office

September 24, 2014

- Freedom to operate confirmed - Successful opposition against Regeneron's patent EP 1 360 287 B1 for transgenic mice producing therapeutic human antibodies Utrecht, The Netherlands, Sept. 18, 2014 - Merus...

Biotech venture capital firm Aglaia launches new $65 mln Oncology fund

September 18, 2014

Bilthoven, the Netherlands, 18 September 2014 - Dutch venture capitalist Aglaia has announced the launch of Aglaia Oncology Fun...

Biotech durfinvesteerder Aglaia start nieuw Oncology Fund met initieel 50 miljoen euro aan kapitaal

September 18, 2014

Bilthoven, 18 september 2014 - Durfinvesteerder Aglaia maakt de start bekend van een nieuw oncologiefonds onder de naam Aglaia Oncology Fund II. Investeerders participeren voor € 50 miljoen. De geplande fon...

ISA Pharmaceuticals Appoints Hendrik-Jan Laseur as Member of the Supervisory Board

September 03, 2014

ISA Pharmaceuticals Appoints Hendrik-Jan Laseur as Member of the Supervisory Board Leiden, The Netherlands, September 3, 2014 - ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on r...

Provincie benut kapitaal uit de markt voor Utrechtse Life Sciences sector

July 10, 2014

De provincie Utrecht heeft Aglaia Biomedical Ventures als professionele fondsbeheerder geselecteerd in het kader van een mandaat voor het aanwenden van € 1.25 miljoen voor ondernemingen in de Utrechtse Life...

ISA Pharmaceuticals Appoints Ronald Loggers as Chief Executive Officer

July 07, 2014

Leiden, The Netherlands, July 07, 2014 - ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, to...

SomantiX and EdgeLeap team-up to mine new anti-angiogenesis targets for cancer therapy

July 02, 2014

SomantiX B.V. in Utrecht and the newly established data analysis company EdgeLeap B.V., founded by former TNO members will join...

New Clinical Data Demonstrate Strong Synergy between Cancer Vaccine ISA101 and Chemotherapy

April 10, 2014

- Data presented at the AACR Annual Meeting 2014 - Potential new treatment being developed for patients with late-stage cervical cancer Leiden, The Netherlands, April 10, 2014 - ISA Pharmaceuticals B.V.,...

New Clinical Data on Cancer Vaccine ISA101 to Be Presented at the AACR Annual Meeting 2014

March 27, 2014

Leiden, The Netherlands, March 27, 2014 - ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infections,...

ORCA Therapeutics granted Chinese Patent covering its T1 oncolytic adenovirus technology

March 22, 2014

Amsterdam, The Netherlands - March 20th, 2013 - ORCA Therapeutics BV, a pioneer in the development of innovative virotherapies for treatment of cancer, announces today that it has secured key intellectual pr...